Debra Jih, MD
Dermatopathology · Philadelphia, PANPI 1790722981
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 32.6% of the total. Reporting peaked in 2023 at $555 and has fallen 94.6% since, to $30 in 2025.
Across 75 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$564
- Biofrontera Inc.$156
- Incyte Corporation$153
- Verrica Pharmaceuticals Inc.$152
- Johnson & Johnson$134
- Lilly USA, LLC$91
- plus $479 from 10 others
What the payments were for
- Food & beverage$1,729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 23 | $564 |
| Biofrontera Inc. | 2 | $156 |
| Incyte Corporation | 7 | $153 |
| Verrica Pharmaceuticals Inc. | 1 | $152 |
| Johnson & Johnson | 8 | $134 |
| Lilly USA, LLC | 6 | $91 |
| Regeneron Healthcare Solutions, Inc. | 5 | $89 |
| Pfizer | 4 | $76 |
| UCB, Inc. | 4 | $71 |
| LEO Pharma Inc. | 4 | $65 |
| Sun Pharmaceutical Industries Inc. | 3 | $52 |
| Amgen | 3 | $40 |
| DUSA Pharmaceuticals, Inc. | 2 | $34 |
| Aclaris Therapeutics, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Journey Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- YCANTH$152
- AMELUZ$136
- BF-RhodoLED$136
- XEPI$136
- Rinvoq$122
How this compares
$1,729 in reported general payments places this provider in the 80th percentile of 27 dermatopathology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketoconazole | 111 | $2,029 |
| Ammonium Lactate | 84 | $1,122 |
| Tacrolimus | 13 | $1,045 |
| Clobetasol Propionate | 25 | $936 |
| Fluorouracil | 19 | $836 |
| ValacyclovirValacyclovir Hcl | 13 | $354 |
| Ciclopirox | 15 | $323 |
| Triamcinolone Acetonide | 34 | $134 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in Philadelphia
- John SeykoraPhiladelphia$19K
- Jina ChungPhiladelphia$918
- Alicia RosenPhiladelphia$252
- Herbert AllenPhiladelphia$203
- Michael MingPhiladelphia$133
- Elizabeth SpiersDoylestown$65K
- Christine StankoVillanova$5K
- Basil PatelYardley$4K
- Victoria Cirillo HylanBryn Mawr$4K
- Howard AltmanAllentown$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.